|Dr. Jean-Paul Kress M.D.||Chairman of Management Board, MD & CEO||2.06M||N/A||1965|
|Dr. Malte Peters M.D.||Chief R&D Officer and Member of the Management Board||1.18M||N/A||1962|
|Mr. Sung H. Lee||CFO & Member of Management Board||N/A||N/A||1970|
|Mr. Klaus De Wall||Head of Accounting & Tax||N/A||N/A||N/A|
|Ms. Lara Smith Weber||Head of Controlling, Corp. Fin. & Corp. Devel.||N/A||N/A||N/A|
|Dr. Margit Urban||Head of Discovery Alliances & Technologies||N/A||N/A||N/A|
|Dr. Anja Pomrehn||Sr. VP & Head of Investor Relations||N/A||N/A||N/A|
|Dr. Armin Weidmann||Head of Compliance and Quality Assurance||N/A||N/A||N/A|
|Ms. Charlotte Lohmann||Sr. VP & Gen. Counsel||N/A||N/A||1970|
|Mr. Thomas Biegi||VP & Head of Corp. Communications||N/A||N/A||N/A|
MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; and MOR106, an antibody for atopic dermatitis. It also develops Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.
MorphoSys AG’s ISS governance QualityScore as of 26 September 2021 is 1. The pillar scores are Audit: 5; Board: 1; Shareholder rights: 1; Compensation: 2.